Grail Inc (GRAL)

Currency in USD
74.84
+5.36(+7.71%)
Closed·
74.21-0.63(-0.84%)
·
GRAL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
68.9076.00
52 wk Range
29.95118.84
Key Statistics
Prev. Close
74.84
Open
69.27
Day's Range
68.9-76
52 wk Range
29.95-118.84
Volume
1.39M
Average Volume (3m)
702.09K
1-Year Change
128.9385%
Book Value / Share
59.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRAL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
70.13
Downside
-6.30%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile

Grail Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
5 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 70.13
(-6.30% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Hold65.00-13.15%58.00Maintain15-07-2026
Baird
Buy77.00+2.89%70.00Maintain13-07-2026
Goldman Sachs
Hold60.00-19.83%-New Coverage05-06-2026
Wolfe Research
Hold---New Coverage01-06-2026
TD Cowen
Buy69.00-7.80%65.00Maintain06-05-2026

Grail Inc Earnings Call Summary for Q2/2026

  • GRAIL Q2 revenue hit $44.7M, beating estimates by 3.5% with 26% YoY growth; test volume surged 35% to 61,000 tests driven by screening sales.
  • Shares dropped 8.33% after-hours despite revenue beat as adjusted EBITDA loss widened to $90.3M from $78.4M YoY; net loss remained $110.2M.
  • Company expects FDA advisory committee meeting fall 2026 with potential approval in early 2027, viewed as critical catalyst for payer coverage.
  • Cash position stands at $861.6M including $110M Samsung investment; Illumina 7% royalty resumes Q4 2026, potentially impacting 2027 margins.
  • Management expanded sales force ahead of FDA decision; average test price fell to ~$700 due to strategic mix shift toward digital health partnerships.
Last Updated: 06-08-2026, 03:02 am
Read Full Transcript

Earnings

Latest Release
05-08-2026
EPS / Forecast
-2.56 / --
Revenue / Forecast
44.7M / 43.2M
EPS Revisions
Last 90 days

GRAL Income Statement

Compare GRAL to Peers and Sector

Metrics to compare
GRAL
Peers
Sector
Relationship
P/E Ratio
−8.5x−14.4x−0.4x
PEG Ratio
−0.34−1.290.00
Price/Book
1.3x6.6x2.6x
Price / LTM Sales
20.2x22.2x3.1x
Upside (Analyst Target)
−6.5%0.9%48.2%
Fair Value Upside
Unlock−43.0%5.8%Unlock

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.70M26.19%875.52M
Other Institutional Investors
30.90M69.19%2.31B
Public Companies & Retail Investors
2.06M4.62%154.38M
Total
44.67M100.00%3.34B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Baker Bros. Advisors LP9.02%40,28,6143,01,501
BlackRock, Inc.7.56%33,76,0852,52,666

FAQ

What Is the Grail (GRAL) Share Price Today?

The Grail share price today is 74.84.

What is the current Grail (GRAL) share price and day range?

As of 11-08-2026, the Grail share price is 74.84, with a previous close of 74.84. The share price has ranged from 68.90 to 76.00 today, while the 52-week range spans from 29.95 to 118.84.

What Is the Grail Market Cap?

As of today, Grail market cap is 3.34B.

What Is the Grail (GRAL) Share Price Target?

The average 12-month share price target for Grail is 70.13, with a high estimate of 88 and a low estimate of 56. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and -6.30% Downside potential.

What Is Grail's Earnings Per Share (TTM)?

The Grail EPS (TTM) is -9.75.

When Is the Next Grail Earnings Date?

Grail will release its next earnings report on 05-08-2026.

From a Technical Analysis Perspective, Is GRAL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Grail Trade On?

Grail is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Grail?

The stock symbol for Grail is "GRAL."

How Many Times Has Grail Stock Split?

Grail has split 0 times.

How Many Employees Does Grail Have?

Grail has 910 employees.

What Is the GRAL Premarket Price?

GRAL's last pre-market stock price is 74.21. The pre-market share volume is 70.00, and the stock has changed by -0.63, or -0.84%.

What Is the GRAL After Hours Price?

GRAL's last after hours stock price is 74.82, the stock has changed by -0.02, or -0.03%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.